Filter Results

Locations

Study status

(for at least one location)

Gender

Age

Healthy Volunteer

What is this?
A volunteer subject with no known significant health problems who participates in research to test a new drug, device or intervention. These volunteers are recruited to serve as controls for patient groups. Healthy volunteers receive the same test, procedure, or drug the patient group receives.

Study phase

What is this?
During the early phases (phases 1 and 2), researchers assess safety, side effects, optimal dosages and risks/benefits. In the later phase (phase 3), researchers study whether the treatment works better than the current standard therapy. They also compare the safety of the new treatment with that of current treatments. Phase 3 trials include large numbers of people to make sure that the result is valid. There are also less common very early (phase 0) and later (phase 4) phases. Phase 0 trials are small trials that help researchers decide if a new agent should be tested in a phase 1 trial. Phase 4 trials look at long-term safety and effectiveness, after a new treatment has been approved and is on the market.

Search Results 41-50 of 132 for Epilepsy

Edit search filters
  1. EEG Cap for Identification of Non-Convulsive Status Epilepticus

    Jacksonville, FL

  2. Adjunctive Ganaxolone (GNX) Treatment in Children and Adults with Tuberous Sclerosis Complex (TSC)-related Epilepsy (TrustTSC)

    Rochester, MN

  3. RNS® System RESPONSE Study

    Rochester, MN

  4. Perampanel for the Reduction of Seizure Frequency in Patients With High-grade Glioma and Focal Epilepsy

    Jacksonville, FL

  5. A Study of Lacosamide to Treat Neonatal Seizures

    Rochester, MN

  6. Study to Develop a Minimally-Invasive Seizure Gauge

    Rochester, MN

  7. A Study to Treat Patients with Dravet Syndrome Using ZX008

    Rochester, MN

  8. Prophylactic Benzodiazepine versus Reinstitution of Maintenance Antiseizure Drugs following Ictal SPECT

    Jacksonville, FL

  9. A Study to Investigate the Effectiveness and Safety of Cannabidiol (GWP42003-P; CBD) as an Added Treatment for the Seizures Associated with Lennox-Gastaut Syndrome in Children and Adults

    Scottsdale/Phoenix, AZ

  10. An Open Label Extension Study of Cannabidiol (GWP42003-P) in Children and Young Adults With Dravet or Lennox-Gastaut Syndromes

    Rochester, MN

.

Mayo Clinic Footer